Double Switch is a cell based technology for the measurement of protein-protein interactions. Knowledge of interaction partners of a protein is a key contribution for understanding molecular processes, for example in the genesis of cancer.
The Double Switch technology simplifies and accelerates the development of tailored drugs by offering an adaptable system for screening and characterization of drug candidates. DoubleSwitch is a fundamental technology, ultimately based on using the tobacco etch virus protease (TEV protease), either in its entirety, or in a split version, to detect protein-protein interactions in a highly sensitive manner. A considerable number of scientific publications in prime journals demonstrate the characteristics and applications of the technology.
The technology platform also allows the analysis of transient (of short term) interactions, allowing its beneficial use in the identification of new therapeutic targets
According to Frost & Sullivan, the market for cell based assays will grow to over €150 M already in 2014.
Double Switch is protected by US American and European patents. Double Switch has been outlicensed.
Most important related publications
- BMC Biotechnology: Analysis of transient phosphorylation-dependent protein-protein interactions in living mammalian cells using split-TEV
- PubMed:Studying G protein-coupled receptor activation using split-tobacco etch virus assays
- PubMed:Integrated analysis of receptor activation and downstream signaling with EXTassays
- PubMed:Monitoring regulated protein-protein interactions using split TEV.
- PubMed: Salt-inducible kinases regulate growth through the Hippo signalling pathway in Drosophila
- PubMed:Integrated measurement of split TEV and cis-regulatory assays using EXT encoded reporter libraries
- PubMed: Linking cellular signalling to gene expression using EXT-encoded reporter libraries